<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008070</url>
  </required_header>
  <id_info>
    <org_study_id>IVA_01_337_HNAS_16_002</org_study_id>
    <secondary_id>2016-001979-70</secondary_id>
    <nct_id>NCT03008070</nct_id>
  </id_info>
  <brief_title>Phase 2b Study in NASH to Assess IVA337</brief_title>
  <acronym>NATIVE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inventiva Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inventiva Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may
      progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes
      mellitus, or insulin resistance and is very common. However, Treatment of NASH is a
      significant unmet clinical need.

      IVA337 is a next generation pan-PPAR (peroxisome proliferator-activated receptors) agonist
      addressing the pathophysiology of NASH : metabolic, inflammatory and fibrotic.

      The purpose of this research is to evaluate the efficacy and the safety of two doses of
      IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver
      steatosis and moderate to severe necroinflammation without cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized (stratified on diabetes), placebo-controlled, double-blind, parallel-assignment,
      dose-range multicenter study

      There are 3 parallel treatment groups: placebo, IVA337 800mg once a day (Quaque Die, QD) and
      IVA337 1200mg QD (identical tablets of 400mg IVA337 or placebo). Both, patient and
      investigator are blinded.

      For each patient, the study duration will be an overall of 6 to 8 months (with a 10-day to
      4-week selection period, a 24-week treatment period and a 4-week follow-up period).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder analysis based on the improvement of the SAF (steatosis: S, activity : A, and fibrosis: F) activity score.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Responder is defined as a decrease from Baseline of at least 2 points of the SAF activity score combining hepatocellular inflammation and ballooning without worsening of fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with reversal of NASH from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with a change in components of SAF score from baseline to end of treatment : Steatosis, Lobular inflammation, Ballooning, Fibrosis</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry: change in the semi quantitative score of ballooning and stellate cell activation from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis score on a 4-points scale (SAF score) from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis score on modified Ishak score from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis area assessed by morphometry (Collagen Proportionate Area, CPA) from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes change from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Alanine amino transferase (ALT), Aspartate amino transferase (AST), Gamma glutamyl transpeptidase (γGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers change from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>fibrinogen, High-sensitivity C-reactive protein (hs-CRP), alpha2 macroglobulin and haptoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism change from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>(fasting glucose and insulin, Homeostasis model assessment of insulin resistance (HOMA) index and, in subjects with type 2 diabetes mellitus (T2DM), HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main plasma lipids levels change from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Total cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), calculated Low density lipoprotein cholesterol (LDL-C), Triglycerides (TG) and apoA1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin change from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AE) as a measure of safety</measure>
    <time_frame>-4, 0, 4, 10 ,14, 24 weeks</time_frame>
    <description>Frequency and type of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG data change from baseline to end of treatment</measure>
    <time_frame>-4, 4, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs parameters change from baseline to end of treatment</measure>
    <time_frame>-4, 0, 4, 10 ,14, 24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Individual plasma through concentration of IVA337</measure>
    <time_frame>4 , 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory biomarkers change from baseline to end of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>inflammation, lipids, glucids, fibrosis, bone remodeling</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>IVA337 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVA337 400mg, once a day (Quaque Die, QD) with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVA337 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVA337 400mg, once a day (Quaque Die, QD) with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match, once a day (Quaque Die, QD) with food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA337</intervention_name>
    <description>1200mg</description>
    <arm_group_label>IVA337 1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA337</intervention_name>
    <description>800mg</description>
    <arm_group_label>IVA337 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects, age ≥18 years.

          -  NASH histological diagnosis according to the currently accepted definition of both
             EASL and AASLD, requiring the combined presence of steatosis (any degree ≥ 5%) +
             lobular inflammation of any degree + liver cell ballooning of any amount, on a liver
             biopsy performed ≤ 6 months before screening in the study and confirmed by central
             reading during the screening period and

               -  SAF Activity score of 3 or 4 (&gt;2)

               -  SAF Steatosis score ≥ 1

               -  SAF Fibrosis score &lt; 4

          -  Subject agrees to have a liver biopsy performed after 24 weeks of treatment.

          -  Compensated liver disease

          -  No other causes of chronic liver disease (autoimmune, primary biliary cholangitis,
             Hepatitis B virus (HBV), hepatitis C virus (HCV), Wilson's, α-1-antitrypsin
             deficiency, hemochromatosis, etc…).

          -  If applicable, have a stable type 2 diabetes, defined as HbA1c &lt; 8.5% and fasting
             glycemia &lt;10 mmol/L, no changes in medication in the previous 6 months, and no new
             symptoms associated with decompensated diabetes in the previous 3 months.

          -  Have a stable weight since the liver biopsy was performed defined by no more than a 5
             % loss of initial body weight.

          -  Negative pregnancy test or post-menopausal. Women with childbearing potential (i.e.
             fertile, following menarche and until becoming post-menopausal unless permanently
             sterile) must be using a highly effective method of contraception (i.e. combined
             (estrogen and progestogen containing) hormonal/ progestogen-only hormonal
             contraception associated with inhibition of ovulation, intrauterine device,
             intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised
             partner). The contraceptive method will have to be followed for at least one
             menstruation cycle after the end of the study

          -  Subjects having given her/his written informed consent.

        Exclusion Criteria:

          -  Evidence of another form of liver disease.

          -  History of sustained excess alcohol ingestion: daily alcohol consumption &gt; 30 g/day (3
             drinks per day) for males and &gt; 20 g/day (2 drinks per day) for females.

          -  Unstable metabolic condition: Weight change &gt; 5kg in the last three months, diabetes
             with poor glycemic control (HbA1c &gt; 8.5%), introduction of an antidiabetic or of an
             anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the
             past 6 months prior to screening.

          -  History of gastrointestinal malabsorptive bariatric surgery within less than 5 years
             or ingestion of drugs known to produce hepatic steatosis including corticosteroids,
             high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6
             months.

          -  Significant systemic or major illnesses other than liver disease, including congestive
             heart failure (class C and D of the American Heart Association , AHA), unstable
             coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure,
             organ transplantation, serious psychiatric disease, malignancy that, in the opinion of
             the investigator, would preclude treatment with IVA337 and/or adequate follow up.

          -  HB antigen &gt;0, HCV Polymerase chain reaction (PCR) tests &gt;0 (patients with a history
             of HCV infection can be included if HCV PCR is negative since more than 3 years), HIV
             infection.

          -  Pregnancy/lactation or inability to adhere to adequate contraception in women of
             child-bearing potential.

          -  Active malignancy except cutaneous basocellular carcinoma.

          -  Any other condition which, in the opinion of the investigator would impede competence
             or compliance or possibly hinder completion of the study.

          -  Body mass index (BMI) &gt;45 kg/m2.

          -  Type 1 diabètes and type 2 diabetic patient on insulin.

          -  Diabetic ketoacidosis

          -  Fasting Triglycerides &gt; 300 mg/dL.

          -  Hemostasis disorders or current treatment with anticoagulants.

          -  Contra-indication to liver biopsy.

          -  History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease
             event, including myocardial infarction, except patients with only well controlled
             hypertension. Any clinically significant ECG abnormality reported by central ECG
             reading.

          -  Participation in any other clinical study within the previous 3 months.

          -  Have a known hypersensitivity to any of the ingredients or excipients of the
             Investigational medicinal product (IMP)

          -  Be possibly dependent on the Investigator or the sponsor (e.g., including, but not
             limited to, affiliated employee).

          -  Creatine phosphokinase (CPK)&gt;5 x ULN

          -  Osteopenia or any other well documented Bone disease. Patient whitout well documented
             osteopenia treated with vitamin D and/or Calcium based supplements for preventive
             reasons can be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven FRANCQUE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Louis ABTIBOL, MD</last_name>
    <phone>+33 (0)762203432</phone>
    <email>jean-louis.abitbol@inventivapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas ABELLO</last_name>
    <phone>+33(0)699 025 681</phone>
    <email>nicolas.abello@inventivapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flinders Medical Centre Department of Hepatology</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital &amp; The University of Adelaide</name>
      <address>
        <city>Elizabeth Vale</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire Saint-luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Bailey Health Clinic</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CISSS de la Montérégie Centre</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LAIR Centre</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Researchsite S.R.O.</name>
      <address>
        <city>Plzen</city>
        <zip>30100</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klin Med S.R.O.</name>
      <address>
        <city>Praha</city>
        <zip>1200</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut klinické a experimentální medicíny, IKEM</name>
      <address>
        <city>Praha</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud- CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan - Centre Hospitalier Universitaire (CHU) de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RWTH University Hospital</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinischen Klinik IV</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, I. Med. Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona-Università Politecnica delle Marche</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Università degli Studi di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pol. Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Białymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Łodzi</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Chorób Zakaźnych</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro MAJADAHONDA</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virgen de la Victoria University Hospital</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Viszerale Chirurgie und Medizin</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaire de Genève</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epatocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Alcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>peroxisome proliferator-activated receptor (PPAR)</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>IVA337</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

